Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.
UTHR
Strong BuyAPPROVEUnited Therapeutics Corporation · Healthcare · United States · $22.1B · Avg Vol: $253M/d
United Therapeutics generates large cash flow from its pulmonary arterial hypertension franchise, runs a net-cash balance sheet and has been repurchasing shares, producing a strong quality score (Q88), and consensus has been revised up 4.0%. The 1.52% insider selling is modest against that. Nothing adverse is known on accounting, solvency or governance.
COMPANY DESCRIPTION
United Therapeutics Corporation is a biotechnology company dedicated to developing and commercializing innovative therapies for patients with rare and life-threatening diseases, predominantly pulmonary arterial hypertension (PAH) and other cardiopulmonary conditions. The company holds a strong market position through its proprietary drug portfolio and orphan drug designations, addressing significant unmet medical needs in specialized therapeutic areas.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 1.9B | 2.3B | 2.9B | 3.2B | 18.0% | 3.2B | 3.1B | 3.4B | 4.0% |
| EPS | — | 15.98 | 21.04 | 26.44 | 30.13 | 23.5% | 27.91 | 28.16 | 31.03 | 1.5% |
| Shares | — | 46.0M | 47.0M | 44.8M | 43.6M | -5.2% | 42.9M | — | — | — |
| Debt | 800.0M | 800.0M | 700.0M | 300.0M | — | -27.9% | — | — | — | — |
| Equity | — | 4.8B | 6.0B | 6.4B | 7.1B | 13.9% | — | — | — | — |
| Op CF | — | 802.5M | 978.0M | 1.3B | 1.6B | 24.8% | 1.7B | — | — | — |
| Inv CF | — | -811.5M | -719.6M | 417.2M | -551.3M | — | — | — | — | — |
| Fin CF | — | 75.4M | -11.9M | -1.3B | -1.1B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of UTHR are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| UTHR | United Therapeutics Corporation(you) | $22.1B | 86 | Strong Buy |
| VIA.DE | Viatris Inc. | $19.0B | 84 | Strong Buy |
| NBIX | Neurocrine Biosciences, Inc. | $15.7B | 83 | Strong Buy |
| ZTS.MX | Zoetis Inc. | $32.0B | 80 | Buy |
| LNTH | Lantheus Holdings, Inc. | $6.6B | 87 | Strong Buy |
| AMRX | Amneal Pharmaceuticals, Inc. | $6.1B | 84 | Strong Buy |
| ELAN | Elanco Animal Health Incorporated | $12.0B | 68 | Buy |
| INDV | Indivior Pharmaceuticals, Inc. | $4.1B | 94 | Strong Buy |
| LQDA | Liquidia Corporation | $6.1B | 70 | Buy |
| BCRX | BioCryst Pharmaceuticals, Inc. | $2.5B | 89 | Strong Buy |
Peer medians: ROE -25.0% · P/E 31.1x · Gross margin 58.8%